Trial Profile
A multicentre study to evaluate the immunogenicity and safety of GSK Biologicals HPV vaccine (580299) co-administered with Boostrix polio (dTpa-IPV) in healthy female subjects aged 10–18 years.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs DTaP poliovirus vaccine (Primary) ; Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Diphtheria; Human papillomavirus infections; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 01 Feb 2010 Results published in the Journal of Adolescent Health.
- 22 Sep 2008 Actual end date reported as July 2008 by ClinicalTrials.gov.
- 22 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.